Delivery Order SPE2DB20D3104-SPE2DB25FV9P9
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $27,766.85 to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count supply) on August 12, 2025, with an ultimate completion date of August 13, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Ondansetron ODT 4 mg tablets in a quantity of 30 units, with a ceiling value of $13,637.20. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of July 30, 2025, and represents a child contract under AmerisourceBergen's larger federal contract portfolio. AmerisourceBergen Drug Corp, headquartered in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ondansetron ODT 4 MG tablets (30-count) with a contract ceiling value of $1,512.72. This firm fixed price delivery order, which is set to be completed by August 5, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.9 million through December 2026. The award was competitively...
- The Defense Logistics Agency awarded a delivery order valued at $6,179.85 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30. This competitively awarded, non-set-aside contract carries a firm fixed price and is scheduled for completion by August 14, 2025. The award will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ondansetron ODT 8 mg tablets in quantities of 30 units. This competitively awarded, non-set-aside contract carries a ceiling value of $4,328.04 under firm fixed-price terms, with an ultimate completion date of July 31, 2025. The pharmaceutical products will be delivered to the contracting location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $13,916.54 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Ondansetron ODT 4 mg tablets in 30-count units. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $28,456.56 on August 15, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30. The contract employs firm fixed pricing and carries an ultimate completion date of August 18, 2025. This delivery order is issued without a set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania....
- The Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a contract ceiling value of $2,568.44. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is set for ultimate completion by August 15, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,113.82 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets in a 30-count configuration. This contract is classified as firm fixed price with no set-aside designation, indicating it was competitively awarded. The delivery order is set for ultimate completion on August 18, 2025, and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This award...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Ondansetron ODT 8 mg tablets in quantities of 30, with a contract ceiling value of $2,831.66. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The contract is scheduled for ultimate completion on July 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- SPE2DB20D3104Indefinite Delivery Contract
- SPE2DB20D3104-SPE2DB25FV9P9Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,173.92 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count) on August 18, 2025, with an ultimate completion date of August 19, 2025. This contract utilizes firm fixed-price pricing and is not set-aside, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), a $999,999,999 comprehensive pharmaceutical support vehicle that runs through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal military and veteran healthcare systems, supplying a comprehensive range of medications, vaccines, and medical supplies across multiple therapeutic domains. As a major pharmaceutical distributor and healthcare solutions provider, the company has demonstrated capability to meet federal procurement requirements through open competition. Ondansetron, an antiemetic medication commonly used in medical settings, is among the specialized pharmaceuticals distributed through the company's federal contracts to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.2k | 8/18/25 |